A Study of LY3209590 in Participants With Type 2 Diabetes

Exclusion Criteria

• •Have significant lipohypertrophy in the target abdominal injection
• •Have a history of renal impairment
• •Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children)
• •Have proliferative retinopathy or maculopathy and/or severe neuropathy
• •Any significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening
• •Require daily insulin treatment less than (\<) 0.15 unit/kilogram (U/kg) per body weight
• •Are treated with a continuous subcutaneous insulin infusion (CSII) pump
• •Currently receiving degludec insulin therapy, or have been treated with degludec within the past 90 days